Phase 3 Readout~month

Phase 3 Topline: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-106584

Indication
Major Depressive Disorder

Other upcoming events for NBIX

Phase 3 ReadoutPhase 3 Topline: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-106584
Phase 3 ReadoutPhase 3 Topline: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-106584
Phase 3 ReadoutPhase 3 Topline: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecer
Phase 3 ReadoutPhase 3 Topline: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecer
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, S

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-106584 — NBIX Phase 3 Readout | BioSniper